AKAditya Kunte

Aditya Kunte

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Aditya Kunte has a total of 65 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Prehabilitation and Early Recovery After Surgery (ERAS) in head and neck cancers: a protocol for a prospective, stratified, open-label randomised controlled trial in adults (PreERA)

    by Reshma Ambulkar, Bhakti Deshmukh, Pravin Dhakane, Shriyal Prabhudesai, Aditya Kunte, Poonam Joshi, Sudhir Nair, Pankaj Chaturvedi

  • Expanding the Abdominal Domain: Long‐Term Success of the Vascularized Posterior Rectus Sheath–Liver Composite Allograft

    by Anurag Shrimal, Arka Banerjee, Vaishnavi Chakravarthy, Rohan J Choudhary, Amit Chopde, Aditya Kunte, Manish C Varma

    Background: Achieving a tension‐free abdominal wall closure in liver transplantation (LT) is challenging, particularly in the presence of donor–recipient size mismatch, prior surgeries, or loss of abdominal domain. These difficulties are amplified when expanded‐criteria donor (ECD) grafts are used, as graft reduction is unsafe and prolonging cold ischemia time (CIT) is not feasible. A vascularized posterior rectus sheath (PRS) allograft, supplied via the hepatic falciform artery (HFA), offers physiological abdominal domain expansion without the infection risks associated with prosthetic meshes or non‐vascularized fascia. Methods: A retrospective review was conducted of all patients undergoing LT with a vascularized PRS allograft at our center. PRS retrieval and implantation were performed using a standardized technique. All patients received conventional immunosuppression. Recipient and donor characteristics, postoperative outcomes, and long‐term follow‐up were analyzed. Results: Five patients (four adults, one child) received a composite liver–PRS allograft. Median donor–recipient weight ratio was 1.7 (range: 1.46–2.18). All grafts met ECD criteria. Mean CIT and warm ischemia time were 4 ± 1.01 h and 43.6 ± 9.54 min, respectively. Primary fascial closure was achieved in all patients without graft infection, abdominal wall infection, or PRS necrosis. One patient developed a rectus sheath hematoma requiring drainage, and another developed a postoperative bulge requiring plication. Median long‐term follow‐up of 9.1 (range: 8.38–10.63) years demonstrated durable fascial integrity. Conclusion: The vascularized PRS allograft is a simple, reproducible, single‐stage solution for abdominal closure in LT, particularly valuable when using ECD grafts, minimizing infection risk, reexplorations, and prolonged CIT.

  • Top Cited Papers
    Open Access

    Impact of Prehabilitation in Major Gastrointestinal Oncological Surgery: a Systematic Review

    by Reshma Ambulkar, Aditya Kunte, Sohan Lal Solanki, Veer Thakkar, Bhakti Deshmukh, Pankaj Singh Rana

    Background Patients undergoing major gastrointestinal oncologic surgeries often present with frailty, sarcopenia, anemia, and comorbidities that reduce physiological reserves and impair recovery. Prehabilitation is a proactive, multidisciplinary approach designed to optimize patient’s health before surgery, thereby enhancing their capacity to tolerate surgical stress. Evidence indicates that prehabilitation can lead to shorter hospital stays, reduced intensive care admissions, a lower incidence of postoperative complications, and improved long-term quality of life. Methods This systematic review is aimed at comprehensively evaluating the current evidence on prehabilitation in gastrointestinal and hepatopancreatobiliary (HPB) surgeries, examining its components, mechanisms of benefit, and barriers to implementation. It also explores the effectiveness of multimodal prehabilitation programs and highlights areas for future research. A systematic search of “PubMed/MEDLINE,” “Google Scholar,” “Scopus,” “Cochrane Library,” “ClinicalTrials.gov,” and “POPLINE” databases was conducted using a combination of Medical Subject Headings (MeSH) and keywords, including Prehabilitation, Anemia Correction, Nutrition Therapy, Physical Exercise, Gastrointestinal Cancer Surgeries, Hepato-Pancreato-Biliary Surgeries, Rehabilitation, and Postoperative Outcomes. Studies involving gastrointestinal cancer patients undergoing surgery, published between 1960 and June 2024, were included. Results Multimodal prehabilitation programs demonstrated significant improvements in functional capacity, reductions in postoperative complications, shorter lengths of stay, and enhanced recovery. However, the strength of evidence varied by cancer type, with robust data supporting prehabilitation in colorectal surgeries and more limited evidence for HPB and upper gastrointestinal surgeries. Home-based programs showed mixed results, with adherence challenges potentially undermining their effectiveness. Inpatient supervised programs were more effective but associated with higher costs. Conclusion Prehabilitation holds promise as a transformative strategy in the perioperative care of gastrointestinal cancer patients. While it improves functional and clinical outcomes, significant barriers such as implementation costs, patient adherence, and variability in program design must be addressed. Future research should focus on tailoring prehabilitation for different cancer types, developing cost-effective models, and conducting high-quality trials to establish standardized guidelines. Integrating prehabilitation into routine clinical practice can significantly enhance surgical outcomes and patient quality of life.


  • Long-Term Sustainability of Peri-Operative Infection Control Practices: Implementation of “Clean Cut,” a Checklist-Based Quality Improvement Program in India

    by Reshma Ambulkar, Aditya R. Kunte, Akanksha Sarangi, Sudhir Nair, Tihitena Negussie, Isabela Lima, Mansi Tara

    Introduction: Surgical site infections (SSIs) are a substantial healthcare burden in low- and middle- income countries. “Clean Cut” is a checklist-based infection prevention and control (IPC) program intended to improve compliance to peri-operative IPC standards. We aim to study the short-term and long-term impact of its implementation in a tertiary care cancer referral center. Methods: This was a single institute, prospective interventional study. Patients undergoing elective head-neck surgical procedures were included. The “Clean Cut” program consisting of surveillance, audits, and IPC training was implemented for 6 months, after which there was no active oversight. Post-intervention (T2) and 1-year follow-up (T3) data regarding compliance to core IPC practices and SSI rates were compared with baseline (T1). Results: One hundred eighty six patients were included with 50 (26.9%), 86 (46.2%), and 50 (26.9%) patients at T1, T2, and T3, respectively. At baseline, teams complied with a mean of 3.56 of the six critical components of infection control processes which rose to 4.66 (p < 0.001) at T2, but decreased to 4.02 at T3 (p = 0.053). The SSI rate at baseline decreased significantly after Clean Cut implementation [16 (32%) vs. 12 (13.95%), p = 0.012], but returned to baseline levels after 1 year [17 (34%), p = 0.006]. Conclusion: Implementation of the “Clean Cut” program increases compliance to infection control processes and reduces SSI rates in the short term. Without continuing oversight, these rates return to baseline values after 1 year.


  • Open Access

    Impact of post-hepatectomy biliary leaks on long-term survival in different liver tumors: A single institute experience

    by Devesh Sanjeev Ballal, Shraddha Patkar, Aditya Kunte, Sridhar Sundaram, Nitin Shetty, Kunal Gala, Suyash Kulkarni, Mahesh Goel

    Devesh Sanjeev Ballal, Shraddha Patkar, Aditya Kunte, Sridhar Sundaram, Nitin Shetty, Kunal Gala, Suyash Kulkarni, Mahesh Goel. Ann Hepatobiliary Pancreat Surg -0001;0:. https://doi.org/10.14701/ahbps.24-078


  • Open Access

    Evolution and improved outcomes in the era of multimodality treatment for extended pancreatectomy

    by Vikram A Chaudhari, Aditya R Kunte, Amit N Chopde, Vikas Ostwal, Anant Ramaswamy, Reena Engineer, Prabhat Bhargava, Munita Bal, Nitin Shetty, Suyash Kulkarni, et al.

    The evolution and outcomes of extended pancreatectomies at a single institute over 15 years are presented in this study. A retrospective analysis of the institutional database was performed from 2015 to 2022 (period B). Patients undergoing extended pancreatic resections, as defined by the International Study Group for Pancreatic Surgery, were included. Perioperative and survival outcomes were compared with data from 2007–2015 (period A). Regression analyses were used to identify factors affecting postoperative and long-term survival outcomes. A total of 197 (16.1%) patients underwent an extended resection in period B compared to 63 (9.2%) in period A. Higher proportions of borderline resectable (5 (18.5%) versus 51 (47.7%), P = 0.011) and locally advanced tumours (1 (3.7%) versus 24 (22.4%), P < 0.001) were resected in period B with more frequent use of neoadjuvant therapy (6 (22.2%) versus 79 (73.8%), P < 0.001). Perioperative mortality (4 (6.0%) versus 12 (6.1%), P = 0.81) and morbidity (23 (36.5%) versus 83 (42.1%), P = 0.57) rates were comparable. The overall survival for patients with pancreatic adenocarcinoma was similar in both periods (17.5 (95% c.i. 6.77 to 28.22) versus 18.3 (95% c.i. 7.91 to 28.68) months, P = 0.958). Resectable, node-positive tumours had a longer disease-free survival (DFS) in period B (5.81 (95% c.i. 1.73 to 9.89) versus 14.03 (95% c.i. 5.7 to 22.35) months, P = 0.018). Increasingly complex pancreatic resections were performed with consistent perioperative outcomes and improved DFS compared to the earlier period. A graduated approach to escalating surgical complexity, multimodality treatment, and judicious patient selection enables the resection of advanced pancreatic tumours.


  • Open Access

    Factors Predicting Prognosis in Metastatic Grade 1 Gastro-entero-pancreatic Neuroendocrine Tumors

    by Saneya A. Pandrowala, Deeksha Kapoor, Aditya Kunte, Amit Chopde, Ameya Puranik, Indraja Devidas Dev, Rahul Parghane, Sandip Basu, Anant Ramaswamy, Vikas Ostwal, et al.

    Introduction: The incidence of gastroenteropancreatic neuroendocrine tumors (GEP-NET) has steadily increased. These tumors are considered relatively indolent even when metastatic. What determines survival outcomes in such situations is understudied. Materials and Methods: Retrospective analysis of a prospectively maintained NET clinic database, to include patients of metastatic grade 1 GEP-NET, from January 2018 to December 2021, to assess factors affecting progression-free survival (PFS). Results: Of the 589 patients of GEP-NET treated during the study period, 100 were grade 1, with radiological evidence of distant metastasis. The median age was 50 years, with 67% being men. Of these, 15 patients were observed, while 85 patients received treatment in the form of surgery (n = 32), peptide receptor radionuclide therapy (n = 50), octreotide LAR (n = 22), and/or chemotherapy (n = 4), either as a single modality or multi-modality treatment. The median (PFS) was 54.5 months. The estimated 3-year PFS and 3-year overall survival rates were 72.3% (SE 0.048) and 93.4% (SE 0.026), respectively. On Cox regression, a high liver tumor burden was the only independent predictor of PFS (OR 3.443, p = 0.014). The 5-year OS of patients with concomitant extra-hepatic disease was significantly lower than that of patients with liver-limited disease (70.7% vs. 100%, p = 0.017). Conclusion: A higher burden of liver disease is associated with shorter PFS in patients with metastatic grade I GEP-NETs. The OS is significantly lower in patients with associated extrahepatic involvement. These parameters may justify a more aggressive treatment approach in metastatic grade 1 GEP-NETs.


  • Comparison of age-stratified survival outcomes of gallbladder cancers in an Indian population

    by Shraddha Patkar, Aditya Kunte, Gurudutt P. Varty, Anant Ramaswamy, Prabhat Bhargava, Vikas Ostwal, Mahesh Goel


  • Open Access

    Evaluation of perioperative routine coagulation testing versus thromboelastography for major liver resection – A single-arm, prospective, interventional trial (PORTAL trial)

    by Reshma Ambulkar, Vignesh Baskar, Shraddha Patkar, Aditya Kunte, Vandana Agarwal, Sohan Lal Solanki, Jigeeshu V Divatia

    Background and Aims: The International Normalised Ratio (INR), which assesses the loss of procoagulant factors in the extrinsic pathway, fails to evaluate the coagulation abnormalities comprehensively after a major liver resection, which often leads to reduced synthesis of procoagulant and anticoagulant-factors. This study was conducted with an aim to study the trend and compare the results of routine coagulation tests and thromboelastography (TEG) during the perioperative period in patients undergoing major liver resections (≥3 segments). Methods: Twenty-five patients who underwent a major liver resection were enrolled. This prospective, single-arm, interventional study was performed with the primary objective of determining the serial changes in conventional coagulation tests and TEG during the perioperative period in patients undergoing major liver resections, at the preincision period, intraoperative period, postoperatively, at 48 h and on the fifth postoperative day. Transfusion requirements of blood components were also assessed with a TEG-guided replacement strategy. Spearman rank-order correlation was used to study the relationships of coagulation tests (both TEG and conventional tests) at each time point. Results: The prothrombin time (PT)-INR was elevated in 14 patients (56%) at the intraoperative, immediate postoperative and 48-h time points in contrast to the TEG parameters, which remained normal in all patients. Blood component transfusion was avoided in 4, 11 and 10 patients at the intraoperative, immediate postoperative and 48-h time points, respectively. Conclusion: International Normalised Ratio overestimates the coagulopathy in patients undergoing major liver resection, and a thromboelastography-guided transfusion strategy reduces overall transfusion requirements.


  • Outcomes of incidental versus non‐incidental T2 gallbladder cancer: A single‐institute experience of 425 cases

    by Shraddha Patkar, Aditya Kunte, Vikram Chaudhari, Mahesh Goel

    Background: Up to 60% of incidentally detected gallbladder cancers (GBCs) have a primary stage of pathologic T2 stage (pT2), defined by invasion of the peri‐adventitial tissue by the tumour, a plane breached during a simple cholecystectomy. This study assesses the impact of incidental detection of pT2 GBCs on survival outcomes.Methods: Retrospective analysis of pT2 GBCs undergoing a curative resection was performed. Patients who received neoadjuvant chemotherapy before an upfront radical resection were excluded. Outcomes of patients undergoing upfront surgery (uGBC) and incidentally detected tumours (iGBC) were compared.Results: From a total of 1356 patients, 425 patients with pT2 GBCs were included. Of these, 118 (27.7%) and 307 (72.23%) patients were in the uGBC and iGBC groups, respectively. Patients with iGBC had significantly higher locoregional, (62 [19.8%] vs. 11 [9.3%]; p = 0.009), liver, (36 [11.5%] vs. 4 [3.4%]; p = 0.01), and abdominal wall recurrences (23 [7.4%] vs. 1 [0.8%]; p = 0.009). Five‐year disease free survival rates were 68.7% and 49.2% in the uGBC and iGBC groups, respectively (p = 0.013). Five‐year overall survival rates were 71.7% and 64.6% in the uGBC and iGBC groups, respectively (p = 0.317).Conclusions: Incidentally detected pT2 GBCs have significantly poorer outcomes compared to similarly staged patients undergoing an upfront radical cholecystectomy.